ASCO 2017: Talazoparib in Metastatic Breast Cancer With a Germline BRCA1/2 Mutation
Based on the final results of the phase II ABRAZO study, the dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib represents a potential treatment option after platinum-based or multiple cytotoxic chemotherapy regimens for patients with metastatic breast cancer and a germline BRCA1/2 mutation. Nicholas C. Turner, MD, PhD, of Royal Marsden Hospital in London, presented the study findings at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 1007) and noted this agent is being evaluated further in the phase III EMBRACA trial.
A total of 83 heavily pretreated patients with germline BRCA-positive advanced breast cancer took part in this open-label study. The objective response rate was 21% in the 48 patients who initially had responded to platinum-based chemotherapy and then developed disease progression. The objective response rate was 37% in the 35 patients who developed disease progression after several lines of nonplatinum-based chemotherapy.
The most common adverse events associated with the use of talazoparib were anemia (52%), fatigue (45%), nausea (42%), diarrhea (33%), thrombocytopenia (33%), and neutropenia (27%). The grade 3 or 4 adverse events reported in at least 10% of patients included anemia, thrombocytopenia, and neutropenia. No nonhematologic adverse events grade 3 or greater were reported.